550 related articles for article (PubMed ID: 28967863)
1. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
2. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
3. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes.
Raab JR; Resnick S; Magnuson T
PLoS Genet; 2015 Dec; 11(12):e1005748. PubMed ID: 26716708
[TBL] [Abstract][Full Text] [Related]
5. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
Mandal J; Mandal P; Wang TL; Shih IM
J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of expression of ARID1A and ARID1B subunits in mouse embryos and in cells during the cell cycle.
Flores-Alcantar A; Gonzalez-Sandoval A; Escalante-Alcalde D; LomelĂ H
Cell Tissue Res; 2011 Jul; 345(1):137-48. PubMed ID: 21647563
[TBL] [Abstract][Full Text] [Related]
7. ARID1B is a specific vulnerability in ARID1A-mutant cancers.
Helming KC; Wang X; Wilson BG; Vazquez F; Haswell JR; Manchester HE; Kim Y; Kryukov GV; Ghandi M; Aguirre AJ; Jagani Z; Wang Z; Garraway LA; Hahn WC; Roberts CW
Nat Med; 2014 Mar; 20(3):251-4. PubMed ID: 24562383
[TBL] [Abstract][Full Text] [Related]
8. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.
Watanabe R; Ui A; Kanno S; Ogiwara H; Nagase T; Kohno T; Yasui A
Cancer Res; 2014 May; 74(9):2465-75. PubMed ID: 24788099
[TBL] [Abstract][Full Text] [Related]
9. The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II.
Trizzino M; Barbieri E; Petracovici A; Wu S; Welsh SA; Owens TA; Licciulli S; Zhang R; Gardini A
Cell Rep; 2018 Jun; 23(13):3933-3945. PubMed ID: 29949775
[TBL] [Abstract][Full Text] [Related]
10. ARID1A loss in cancer: Towards a mechanistic understanding.
Mathur R
Pharmacol Ther; 2018 Oct; 190():15-23. PubMed ID: 29730444
[TBL] [Abstract][Full Text] [Related]
11. ARID1A-dependent maintenance of H3.3 is required for repressive CHD4-ZMYND8 chromatin interactions at super-enhancers.
Reske JJ; Wilson MR; Armistead B; Harkins S; Perez C; Hrit J; Adams M; Rothbart SB; Missmer SA; Fazleabas AT; Chandler RL
BMC Biol; 2022 Sep; 20(1):209. PubMed ID: 36153585
[TBL] [Abstract][Full Text] [Related]
12. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice.
Mathur R; Alver BH; San Roman AK; Wilson BG; Wang X; Agoston AT; Park PJ; Shivdasani RA; Roberts CW
Nat Genet; 2017 Feb; 49(2):296-302. PubMed ID: 27941798
[TBL] [Abstract][Full Text] [Related]
13. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
14. Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response.
Niedermaier B; Sak A; Zernickel E; Xu S; Groneberg M; Stuschke M
Sci Rep; 2019 Dec; 9(1):18207. PubMed ID: 31796878
[TBL] [Abstract][Full Text] [Related]
15. SKOV3 cells containing a truncated ARID1a protein have a restricted genome-wide response to glucocorticoids.
Stubbs FE; Birnie MT; Biddie SC; Lightman SL; Conway-Campbell BL
Mol Cell Endocrinol; 2018 Feb; 461():226-235. PubMed ID: 28942102
[TBL] [Abstract][Full Text] [Related]
16. Potential therapeutic targets in ARID1A-mutated cancers.
Bitler BG; Fatkhutdinov N; Zhang R
Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
[TBL] [Abstract][Full Text] [Related]
17. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
18. ARID1a-DNA interactions are required for promoter occupancy by SWI/SNF.
Chandler RL; Brennan J; Schisler JC; Serber D; Patterson C; Magnuson T
Mol Cell Biol; 2013 Jan; 33(2):265-80. PubMed ID: 23129809
[TBL] [Abstract][Full Text] [Related]
19. Two related ARID family proteins are alternative subunits of human SWI/SNF complexes.
Wang X; Nagl NG; Wilsker D; Van Scoy M; Pacchione S; Yaciuk P; Dallas PB; Moran E
Biochem J; 2004 Oct; 383(Pt 2):319-25. PubMed ID: 15170388
[TBL] [Abstract][Full Text] [Related]
20. Dissecting the role of SWI/SNF component ARID1B in steady-state hematopoiesis.
Madan V; Shyamsunder P; Dakle P; Woon TW; Han L; Cao Z; Nordin HBM; Jizhong S; Shuizhou Y; Hossain MZ; Koeffler HP
Blood Adv; 2023 Nov; 7(21):6553-6566. PubMed ID: 37611161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]